Identification of miRNA-Based Signature as a Novel Potential Prognostic Biomarker in Patients with Breast Cancer.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
17
07
2019
revised:
03
10
2019
accepted:
17
10
2019
entrez:
25
1
2020
pubmed:
25
1
2020
medline:
15
5
2020
Statut:
epublish
Résumé
To identify the novel, noninvasive biomarkers to assess the outcome and prognosis of breast cancer (BC), patients with high sensitivity and specificity are greatly desired. Herein, the miRNA expression profile and matched clinical features of BC patients were extracted from The Cancer Genome Atlas (TCGA) database. The preliminary candidates were screened out by the univariate Cox regression test. Then, with the help of LASSO Cox regression analysis, the hsa-let-7b, hsa-mir-101-2, hsa-mir-135a-2, hsa-mir-22, hsa-mir-30a, hsa-mir-31, hsa-mir-3130-1, hsa-mir-320b-1, hsa-mir-3678, hsa-mir-4662a, hsa-mir-4772, hsa-mir-493, hsa-mir-556, hsa-mir-652, hsa-mir-6733, hsa-mir-874, and hsa-mir-9-3 were selected to construct the overall survival (OS) predicting signature, while the hsa-mir-130a, hsa-mir-204, hsa-mir-217, hsa-mir-223, hsa-mir-24-2, hsa-mir-29b-1, hsa-mir-363, hsa-mir-5001, hsa-mir-514a-1, hsa-mir-624, hsa-mir-639, hsa-mir-659, and hsa-mir-6892 were adopted to establish the recurrence-free survival (RFS) predicting signature. Referring to the median risk scores generated by the OS and RFS formulas, respectively, subgroup patients with high risk were strongly related to a poor OS and RFS revealed by Kaplan-Meier (K-M) plots. Meanwhile, receiver operating curve (ROC) analysis validated the accuracy and stability of these two signatures. When stratified by clinical features, such as tumor stage, age, and molecular subtypes, we found that the miRNA-based OS and RFS classifiers were still significant in predicting OS/RFS and showed the best predictive values than any other features. Besides, functional prediction analyses showed that these targeted genes of the enrolled miRNAs were enriched in cancer-associated pathways, such as MAPK/RTK, Ras, and PI3K-Akt signaling pathways. In summary, our observations demonstrate that the novel miRNA-based OS and RFS signatures are independent prognostic indicators for BC patients and worthy to be validated by further prospective studies.
Identifiants
pubmed: 31976020
doi: 10.1155/2019/3815952
pmc: PMC6954483
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3815952Informations de copyright
Copyright © 2019 Jia Tang et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Biomark Res. 2015 Jun 06;3:12
pubmed: 26120471
Nucleic Acids Res. 2015 Jan;43(Database issue):D146-52
pubmed: 25378301
Cell Oncol (Dordr). 2016 Feb;39(1):23-33
pubmed: 26458815
Nat Rev Genet. 2004 Jul;5(7):522-31
pubmed: 15211354
PLoS One. 2017 Apr 24;12(4):e0176395
pubmed: 28437471
Transl Oncol. 2010 Feb;3(1):1-12
pubmed: 20165689
Cancer Res. 2009 Jul 15;69(14):5936-45
pubmed: 19549897
Cancer Res. 2019 Apr 1;79(7):1520-1534
pubmed: 30737233
Exp Ther Med. 2017 Aug;14(2):1009-1016
pubmed: 28781618
Biochem Biophys Res Commun. 2018 Jun 22;501(2):486-493
pubmed: 29746865
Front Med (Lausanne). 2018 Sep 04;5:248
pubmed: 30234119
Lancet Oncol. 2016 Aug;17(8):1137-1146
pubmed: 27402147
Med Sci Monit. 2017 Apr 18;23:1857-1871
pubmed: 28416776
Med Sci Monit. 2018 Jun 12;24:3987-3996
pubmed: 29893377
Mol Carcinog. 2014 Jan;53(1):38-48
pubmed: 22911661
PLoS One. 2014 Jan 24;9(1):e86319
pubmed: 24475105
Oncotarget. 2016 Mar 15;7(11):12267-85
pubmed: 26943585
Breast Cancer Res Treat. 2018 Sep;171(2):247-259
pubmed: 29948402
Oncotarget. 2018 Sep 11;9(71):33577-33588
pubmed: 30323900
Front Neurosci. 2019 Mar 22;13:257
pubmed: 30967757
Proc Natl Acad Sci U S A. 2013 Apr 30;110(18):7413-7
pubmed: 23589849
Biomed Pharmacother. 2016 Mar;78:335-341
pubmed: 26898459
OMICS. 2018 Nov;22(11):709-716
pubmed: 30388053
Nucleic Acids Res. 2018 Jan 4;46(D1):D296-D302
pubmed: 29126174
PLoS One. 2014 Feb 28;9(2):e89700
pubmed: 24586971
CA Cancer J Clin. 2017 Jul 8;67(4):290-303
pubmed: 28294295
Ann Surg Oncol. 2017 Oct;24(10):2943-2949
pubmed: 28766230
Aging (Albany NY). 2019 Jan 30;11(2):649-662
pubmed: 30696800
Neural Netw. 2019 Mar;111:11-34
pubmed: 30654138
Oncotarget. 2015 Dec 1;6(38):41290-306
pubmed: 26512777
Funct Integr Genomics. 2019 Jul;19(4):645-658
pubmed: 30859354
Clin Lab. 2019 Apr 1;65(4):null
pubmed: 30969075
Am J Transl Res. 2018 Mar 15;10(3):659-669
pubmed: 29636857
Nat Commun. 2017 Oct 19;8(1):1036
pubmed: 29051494
J Breast Cancer. 2016 Jun;19(2):148-55
pubmed: 27382390
Clin Cancer Res. 2015 Mar 1;21(5):1207-14
pubmed: 25547678
Oncotarget. 2018 Apr 3;9(25):17825-17838
pubmed: 29707149
Elife. 2015 Aug 12;4:null
pubmed: 26267216
Oncogene. 2016 Sep 15;35(37):4914-26
pubmed: 26876200
Biometrics. 2008 Mar;64(1):115-23
pubmed: 17608783
Cancer Lett. 2017 Aug 1;400:89-98
pubmed: 28461244
Curr Pharm Des. 2017;23(12):1845-1859
pubmed: 28231756
J Cell Physiol. 2019 Aug;234(10):18970-18984
pubmed: 30916359
Int J Mol Med. 2019 Feb;43(2):1049-1057
pubmed: 30483747
Stat Med. 1997 Feb 28;16(4):385-95
pubmed: 9044528
Int J Biol Markers. 2015 Nov 11;30(4):e347-58
pubmed: 26349663
Lancet Oncol. 2013 Dec;14(13):1295-306
pubmed: 24239208
Med Oncol. 2014 Dec;31(12):347
pubmed: 25416050
Appl Spectrosc. 2013 Oct;67(10):1185-99
pubmed: 24067576